BRIEF-Roche receives FDA approval for complementary pd-l1 biomarker test in Urothelial Carcinoma
May 2 Roche Holding Ag
* Roche receives FDA approval for Complementary PD-l1 (SP263) Biomarker test in Urothelial carcinoma
* Continues to pursue regulatory approval for Ventana PD-l1 assay in other cancer indications in US and in other geographies Source text for Eikon: Further company coverage: